March 1989

Venture Capital: Rx For Tech Transfer Blues? As many of the national labs can attest, inventing a better mouse trap is no guarantee that the world will beat a path to your door. So several government labs have been forced to adopt unusual methods to sell their wares to the private sector. The latest experiment is an $8.5 million venture capital fund set up by Argonne National Lab and the University of Chicago. The privately endowed fund, known as ARCH Venture Fund, is a nonprofit creature form

The Politics Of Filling The Pipeline If you think that an idea as all-American as national science scholars could be able to escape the taint of politics, you’ll have to think again. In last month’s address to Congress, President Bush proposed 570 such scholarships to entice the intellectual cream of U.S. youth to pursue careers in science and engineering, But his $5 million a year program to refill the U.S. science pipeline would be overseen by the Department of Education, and tha

Who needs venture capital? Not Stanford medical researchers whose work shows potential for clinical applications. Last month, Stanford University Hospital announced that it had awarded $351 ,200 to nine projects that need only to be developed a bit further to be ready for clinical testing. These are the first awards made by the hospital under its new technology transfer program, which was announced last summer. In an attempt to speed the transfer of innovative techniques from lab to bedside, th

Industry Scientists: Yale Wants You Now corporate scientists can tap into the brainpower and technical expertise of Yale University cell biologists, thanks to a project just established at the university by its Office of Cooperative Research. For $20,000 (small businesses pay $10,000), members of the Cell Biology Liaison Program are able to visit the school of medicine’s cell biology department laboratories, attend an annual symposium held exclusively for subscribers, participate in tech

Scientific journals welcome new subscribers without reservation. It is a pity that many are far less welcom ing to the other group of people on whom they they depend--their authors. In one sense, it is inevitable that journals do not take pains to accommodate authors. Only a minority of scientists can succeed in having their work regularly published in the most respected and widely read journals in their field. Many papers are rejected by one or more journals before being accepted. What I d

Concern over the pressure to publish and its spawning of fraudulent publications has led to an examination of multiple authorship of scientific papers. In prestigious journals, such as the New England Journal of Medicine and Science, papers with six or more coauthors are not uncommon. While many of the authors may have contributed to the work described in a paper, there are many instances in which names are added to the author list for political reasons. A scientist may supply a needed compou

Taking MacRisks I was dismayed to read that the MacArthur Foundation might he discontinuing its so-called “genius awards” in science (The Scientist, February 6, 1989, page 14). Those awards are among the more imaginative ways of supporting science because they provide the recipients with enough supportto allow some real accomplishment. Corbally, the outgoing president of the founda tion, is quoted as saying that “The fellowships work beautifully for writers, poets, and histor

The accompanying article, in the same issue by Leonard Minsky, and the history of Jerome Jacobstein’s experiences adjoining it, remind us of cases in which universities have chosen to punish the whistlebiower rather than the person who in fact proved to be guilty of fraud. It is of course very difficult to set up a committee that is expert in the scientific field involved in a disptited case, and also free from conflict of interest. I would only insist that such a body cannot be set up w

No Turning Back Garland Allen expresses concern about genetic research on human behavioral traits (The Scientist, February 6, 1989, page 9). His implicit solution, however—ending research and discussion of the genetic basis of human traits—does little more than turn back the clock to a period of ignorance. Do we really want to return to a time when psychiatrists thought that schizophrenia was a result of cold and and loving mothers—and blamed the mother for a child’s i

I would like to bring to your attention a problem that is halting the benefits of medical and anthropological research. It involves the “reburial” movement, which is quite strong in a number of states—for example, California, Oklahoma, and Iowa. A small number of activists, for financial, political, and religious reasons, are insisting that all prehistoric skeletons and artifacts be buried regardless of next-of-kin desires. Reburial in Califomia and several other states is now

Critquing "Critique" Your critique of Dr. Forer’s critique of “critique” as a verb won’t do (The Scientist, December 26, 1988, page 10). The Merriam Webster staff relinquished the right to be a council of last resort when they decided, by inverse snobbery, to regard a word or pronunciation as correct merely because it is often used. A good dictionary should be prescriptive as weil as descriptive. By adopting their misguided policy of sacrificing their prescriptive resp

Fleecing The Public Your account of Sen. William Proxmire’s “Golden Fleece” awards (The Scientist, December 12, 1988, page 17) may be supplemented with the history of his success in obstructing regulation of vitamin products in 1974. The Food and Drug Administration proposed to set an upper limit of 150% of Recommended Daily Allowances (RDAs) per tablet for the over-the-counter vitamin products. There was no restriction on taking several tablets per day, which actu ally is a

Funding Inequities Your story in the December 12 issue of The Scientist concerning NIH funding had the title, “The Rich Get Richer” (page 19). So what’s new? Many of us interacting with the system have known of the institutionalized inequity of the system for years. The reason why these institutions have monopolized the bulk of NIH dollars is because they have seeded the study sections with their own people and friends. The cruel joke is that many people inside the exclusive

False Hope I am most grateful to Paul Raeburn for his article entitled, “Biotherapeutics: Expensive Scam, Or Equal Opportunity” (The Scientist, December 26, 1988, page 7). As a biomedical researcher, a medical school professor, and a metastatic malignant melanoma patient, I believe it important that the public be aware of the overall implications involved in such an endeavor as Biotherapeutics. We all know that immunotherapy is in its developing stage, and I hope it will prove to b

Recent enactment of the U.S.-Canada Free Trade Agreement has been touted by proponents as a move toward cooperation between the two nations that is without precedent. But on the science front, at least, strong collaboration is hardly a new phenomenon. Indeed, it has been dramatically on the rise throughout this decade. Since 1980, scientific cooperation, as reflected in scientific papers written jointly by Canadian and U.S. scientists, has risen sharply. Canadians have increased by a third,

CHEMISTRY BY RON MAGOLDA Medical Products Department E.I. duPont de Nemours & Co. Wilmington, DeL " This publication describes the first total synthesis of the potent immunosuppressant, (-)-FK-506. T.K. Jones, 5.0. Mills, R.A. Reamer, D. Askin, et al, “Total synthesis of the immunosuppressant (-)-FK-506,” Journal of American Chemical Society Ul (3), 1157-1159, February 1, 1989. ( Alanine racemase, a pyridoxal 5’-phosphate containing enzyme, has been inhibited with a number

COMPUTATIONAL SCIENCE BY BRUCE G. BUCHANAN Department of Computer Science University of Pittsburgh Pittsburgh, Pa. " Electronic mail systems simplify communication but often result in information overload, or sometimes a flood of “junk mail.” Or the horizon are software tools that filter messages according tc criteria defined by the individual. This paper describes one such prototype. S. Pollock, “Arnie-based message filtering system,” acm Transactions on Office Infor

LIFE SCIENCES >BY WILLIAM F. LOOMIS Department of Biology University of California, San Diego La Jolla, Calif. " Gene therapy of certain cancers has come a step closer. Neoplasia of retinoblastoma and osteosarcoma cells was suppressed by introducing a functional copy of the RB gene on a retrovirus vector. Unlike the original cell lines, the suppressed cells failed to form tumors when injected into nude mice. H.-J. Huang, J.-K. Yen, J.-Y. Shew, P.-L. Chen, et al, “Suppression of the neop

PHYSICS BY FRANK A. WILCZEK Institute for Theoretical Physics University of California, Santa Barbara Santa Barbara, Calif. A deeply troubling problem for modern physics is why the vacuum doesn’t weigh very much. A recent paper reviews the reasons why this seemingly innocuous fact bothers people, and it presents as well some of the wild speculations this phenomenon has engendered. S. Weinberg; “The Cosmological Constant Problem,” Reviews of Modern Physics, 61 (1), 1, Januar

PLANT AND ANIMAL SCIENCES BY PETER D. MOORE Department of Biology King’s College London, U.K. " The shells of dinosaur eggs developed in a manner that more closely resembles some birds’ eggs than it does modern reptiles’ eggs. The texture changes abruptly in sequential layers as a result of organic material periodically interrupting calcite deposition. This structure is also found in the thick shells of modern rarities such as ostrich and rhea. H. Silyn-Roberts, R.M. Sharp

Spending too much time on electronic mail, lately? Maybe Binet is the culprit—and maybe you’d like an alternative. Among scientists in academia who’ve been bitten by the E-mail bug, Bitnet appears to have emerged as the transmitting/receiving network of choice. Since it’s a network run by a consortium of academic institutions, it’s private----essentially only other academics may use it. And virtually all academic institutions—and the National Science Foun

Three interdisciplinary themes weave through this year’s annual meeting of the Federation of American Societies for Experimental Biology (FASEB), opening today at the New Orleans Convention Center. These special areas of interest are AIDS, 2nd messengers and signal transduction, and mechanisms of adaptation to the environment: FASEB projects that its huge program of tutorials, society and guest symposia, special lectures, and slide and tape poster sessions, will attract about 13,000 peop